Subscribe to PCMR and stay up-to-date with the only journal committed to publishing basic research in melanoma and pigment cell biology As a member of the IFPCS or the SMR you automatically get online access to PCMR. Sign up as a member today at www.ifpcs.org or at www.societymelanomaresarch.org The expression levels for 10 of the HIF1a direct targets -GAPDH, PKM, PPAT, DARS, DTWD1, SEH1L, ZNF292, RLF, AGTRAP, and GPC6 -are significantly correlated with reduced time of disease-free status in melanoma by logistic regression (P-value = 0.0013) and ROC curve analysis (AUC = 0.826, P-value < 0.0001). This HIF1a-regulated profile defines a melanocyte-specific response under hypoxia, and demonstrates the role of HIF1a as an invasive cell state gatekeeper in regulating cellular metabolism, chromatin and transcriptional regulation, vascularization, and invasion.
Introduction
The incidence of melanoma has increased over the past 20 yr, and it has become clear that early diagnosis and excision of lesions is critical. Removal of early stage lesions correlates with a 5-yr survival rate of over 98%; however, the 5-yr survival rate drops dramatically to 62 and 18% for individuals who have progressed to regional lymph node or distal metastasis, respectively [SEER database (Howlader et al., 2016) ]. Therefore, deciphering the underlying mechanisms that trigger primary lesions to metastasize has both prognostic importance and therapeutic importance.
Current research has identified the most frequent driver mutations that cause melanoma progression, including BRAFV600E [~50% (Bauer et al., 2011) ], NRAS codons G12, G13, and Q61 [~20% (Lee et al., 2011) ], and NF1 loss-of-function mutations [~14% (Cancer Genome Atlas Network, 2015) ], all of which promote increased levels of MAPK signaling. However, the occurrence of these mutations alone does not correlate with clinical measures of outcome in melanoma patients, such as overall survival or disease-free status (DFS) (Rutkowski et al., 2014) , suggesting these mutations alone provide an incomplete understanding of the complexity underlying melanoma metastasis. While one contributing factor may be the heterogeneity of additional genomic melanoma mutations (Cancer Genome Atlas Network, 2015; Hodis et al., 2012) , notable heterogeneity of gene expression in localized tumor regions has been seen within individual lesions. This regional gene expression variation reflects altered protein and transcriptional regulation in response to changing nutrient and oxygen levels in the tumor microenvironment, thus modulating rates of energy production, stem cell renewal, cell proliferation, migration, differentiation, and responsiveness to immune surveillance mechanisms.
Interestingly, the microenvironment for normal melanocytes located at the dermal-epidermal junction is slightly hypoxic. While dermal tissue has an oxygen partial pressure (pO 2 ) of 10%, the adjacent epidermis has a pO 2 that ranges from 10 to 0.5% (Evans et al., 2006) . In melanomas, rapid cell growth within tumors leads to insufficient vascularization, resulting in localized regions of hypoxia that are associated with poor clinical outcomes (Bertout et al., 2008) . Therefore, melanocytes and primary melanoma tumors that arise from skin melanocyte populations must respond to a microenvironment defined by a hypoxic gradient which is further exacerbated by reduced oxygen levels upon tumor growth (Bedogni and Powell, 2009) .
Microenvironmental oxygen concentrations directly regulate the transcription factor hypoxia-inducible factor one alpha subunit [HIF1a (Wang et al., 1995) ]. Under normoxia, HIF1a is tightly regulated at the protein level, undergoing proteosomal degradation that is directed by von HippleLindau protein (VHL) (Ivan et al., 2001; Jaakkola et al., 2001) . At lower oxygen levels, HIF1a protein is retained and translocated to the nucleus, where it can heterodimerize with the constitutively expressed Aryl-HydrocarbonReceptor Nuclear Translocator (ARNT). HIF1a-regulated genes control multiple cellular functions critical in cancer progression, including metabolism, cellular survival and proliferation, tumor invasiveness, vascularization, chromatin remodeling, and escape from adaptive immunity (Semenza, 2013; Wigerup et al., 2016) , suggesting HIF1a and its downstream pathways are important potential targets for therapeutic interventions.
In melanoma, a role for HIF1a in promoting tumorigenesis is well substantiated. The BRAFV600E mutation results in increased HIF1a expression and melanoma cell survival (Kumar et al., 2007) . In addition, elevated HIF1a expression levels correlate with a cellular phenotype switch from a proliferative to invasive phenotype, and this phenotypic plasticity is associated with melanoma drug resistance and poor prognosis (O'Connell et al., 2013; Widmer et al., 2013) . Furthermore, B16F10 mouse melanoma cells exposed to hypoxia prior to injection in nude mice show increased tumor growth and metastatic potential (Cheli et al., 2012) , and conversely loss of HIF1a in a PTEN-deficient, BRAF-activated mouse model of melanoma results in decreased tumor lymph node burden (Hanna et al., 2013) . These mouse melanoma models confirm a crucial in vivo role for HIF1a in regulating the proliferative to invasive cell changes that lead to regional and distal disease progression.
Previous analyses in other tissues have found that HIF1a genome binding and HIF1a-regulated genes are highly tissue-dependent (Benita et al., 2009; Chi et al., 2006; Denko et al., 2003; Widmer et al., 2013) . Currently, there are limited genomic data that define the melanocyte transcriptional responses to HIF1a and hypoxia. This study used ChIP-Seq and differential gene expression analyses to evaluate the genomic landscape that exists within melanocytes under hypoxia and in response to HIF1a knockdown. The resulting data not only define HIF1a genome occupancy and downstream targets in mammalian melanocytes, but also reveal a novel set of HIF1a direct target genes that are significantly correlated with DFS in human primary melanomas, providing critical information for assessing melanoma progression.
Results

Hypoxia-responsive genes in melanocytes
Immortalized melanocytes under hypoxia showed increased migratory capacity and increased HIF1a protein levels in comparison with immortalized melanocytes under normoxia ( Figure 1A , B). Hypoxia-treated melanocytes also showed HIF1a-dependent upregulation of known HIF1a target genes ( Figure 1C ). As expected, Hif1a mRNA was not changed by hypoxia, consistent with the fact that protein stabilization regulates HIF1a function ( Figure 1C ). Subsequent transcriptome analysis found that melanocytes are highly responsive to hypoxic conditions; 709 hypoxia-responsive genes were altered ≥1.5-fold under hypoxia, with 452 genes upregulated and 257 genes downregulated ( Figure 1D , Table S1 ).
Consistent with hypoxia exposure activating HIF1a in melanocytes,~11% (51/452) of the hypoxia-responsive upregulated genes were well-characterized HIF1a targets, and the predicted canonical pathways identified by these genes included glycolysis, gluconeogenesis, axon guidance signaling, and HIF1a signaling (Table S2 ). In addition to HIF1a, the predicted transcriptional regulators included EPAS1/HIF2a, MYC, VHL, and STAT4 (Figure 1D , Table S2 ). These transcription factors linked this upregulated gene cohort of hypoxia-responsive genes in melanocytes to the anticipated HIF1a/HIF2a/ARNT pathway and its regulation by VHL, and also to pathways known to interact with HIF factors (Cancer Genome Atlas Network, 2015; Dang et al., 2008; Xu et al., 2005) .
In contrast, the cellular functions of the 257 downregulated hypoxia-responsive genes included multiple genes involved in pigmentation (Mreg, Oca2, Rab27a, and Slc24a5), DNA replication (Cdc6, Mcm2, Mcm3, Mcm4, Mcm5, Mcm6, Mcm7, and Rrm2) and DNA repair (Chaf1b, Exo1, Dna1, Lig1, Atrx, Rad54l, Fanca, and Pole). Of the top predicted transcriptional regulators identified for the hypoxia-downregulated genes, which included TBX2, E2F family members, and the RB family of transcription factors ( Figure 1D , Table S2 ), only RBL1 itself was also downregulated~twofold in this dataset. This highlights the potential for RBL1 to be an important factor in regulation of the downregulated hypoxia expression profile. In total, these results suggest hypoxia triggers multiple melanocyte cellular responses, characterized by activation of HIF1a pathway genes and repression of Rb-E2F and TBX2 downstream pathway genes.
Previous studies found modest overlap between hypoxia gene expression datasets from different tissues, suggesting hypoxia causes cell type-specific gene expression changes (Benita et al., 2009; Chi et al., 2006; Denko et al., 2003; Widmer et al., 2013) . Direct comparison of eight hypoxia-annotated gene datasets from diverse tissues using gene set enrichment analysis (GSEA) (Subramanian et al., 2005) found that while these GSEA hypoxia-annotated datasets contained a total of 1184 genes that are differentially expressed in response to hypoxia, there was only a 2-28% average overlap between any two datasets. Similarly, the 709 melanocyte hypoxia-responsive gene set exhibited an average 28% overlap with the other eight hypoxia datasets (Table S3) . Gene list comparisons for the eight GSEA hypoxia cells is significantly increased by 24-h hypoxia exposure (***P < 0.0001). Representative images of migration wells for cells grown for 24-h under normoxia (22% O 2 ) and hypoxia (1% O 2 ) are shown below the graph. (B) HIF1a protein is stabilized by 24-h hypoxia, and HIF1a protein expression under hypoxia is eliminated by siHif1a treatment. Molecular weights: HIF1a = 95 kDa, Tubulin = 50 kDa. (C) Hif1a mRNA levels are unchanged under hypoxia, consistent with HIF1a protein stabilization regulating signaling activity. Hif1a mRNA levels are significantly reduced by multiple siRNAs (**P = 0.0015). The mRNA expression levels of the known HIF1a target genes Kdm3a and Gapdh are significantly increased by 24-h hypoxia (*P < 0.05), and are significantly downregulated with siHif1a KD under hypoxia, returning to near-normoxic levels (*P < 0.05). (D) 709 hypoxia-responsive genes were differentially expressed 1.5-fold under normoxia versus hypoxia growth conditions. Ingenuity pathway analysis (IPA) predicted distinct upstream regulatory factors for upregulated and downregulated gene cohorts, listed at right. See Table S1 for the complete list of 709 hypoxia-responsive genes. (E) 712 HIF1a-dependent genes were differentially expressed 1.5-fold in both siHif1a KD RNAs as compared to non-silencing control. IPA predicted distinct upstream regulatory factors for upregulated and downregulated gene cohorts, listed at right. See Table S4 for the complete list of 712 HIF1a-dependent genes. Details of IPA analysis for predicted transcriptional regulators and downstream targets for the hypoxia-responsive genes and the HIF1a-dependent genes are in Tables S2 and S5 , respectively. Norm, normoxia; Hpx, hypoxia; Ctr, control si; si1 and si6, independent HIF1a-directed siRNA constructs.
datasets and the hypoxia-responsive set (nine datasets total) revealed that no gene was consistently altered in all nine datasets, although a subset of genes was contained in at least seven of the nine datasets (Bnip3, Adm, Bhlhe40, Bnip3l, Igfbp3, Mxi1, P4ha1, Slc2a3, and Vegf). These results support a tissue-dependent hypoxia response, and suggest that tissue-specific cofactors and chromatin accessibility may direct many hypoxiamediated gene expression changes.
HIF1a-dependent genes in melanocytes
To assess the direct role of HIF1a in regulating gene expression under hypoxia, melanocytes were subjected to siRNA-mediated HIF1a knockdown (KD) followed by 24-h hypoxia exposure. Under these conditions, multiple Hif1a-directed siRNAs reduced HIF1a protein and mRNA expression, as well as mRNA expression of the known HIF1a target genes Kdm3a and Gapdh ( Figure 1B, C) . Transcriptome analysis using two independent Hif1a-directed siRNAs identified 712 HIF1a-dependent genes that were ≥1.5-fold differentially expressed in comparison with non-silencing controls in both siRNAs ( Figure 1E , Table S4 ). Within this HIF1a-dependent gene set, 362 genes were downregulated by siHIF1a KD, thus representing a HIF1a-activated gene profile. These genes exhibited enrichment of both HIF1a-responsive canonical pathways and predicted upstream regulators that were similar to those observed under hypoxia exposure (Table S5) . A similar number of genes (350) was significantly upregulated upon siHIF1a KD, suggesting these genes are repressed by HIF1a under hypoxia. Canonical pathways enriched for this HIF1a-dependent repressed gene cohort included cell cycle control of cell replication, tRNA charging, and DNA damage response. In addition, these 350 HIF1a-dependent repressed targets were predicted to have E2F4, ATF4, MYC, E2F6, and TBX2 as upstream regulators ( Figure 1E , Table S5 ). Of these predicted transcriptional regulators, expression of ATF4 itself was increased 1.62-fold under HIF1a KD (Table S4) and 17 genes were identified as ATF4 known target genes. Interestingly, 9 of the 17 ATF4 target genes (Slc7a5, Asns, Mthfd2, Psat1, Slc1a5, Shmt2, Trib3, Dit3, and Cth) were associated with MTORC1 signaling. MTORC1 pathways regulate both cell growth and metabolism, and MTORC1 pathway regulation is known to be repressed by hypoxia (Wouters and Koritzinsky, 2008) . In summary, these HIF1a-dependent genes define both activated and repressed gene targets, and also reveal that consistent pathways are regulated by hypoxia and HIF1a in melanocytes.
HIF1a-dependent/hypoxia-responsive melanocyte gene signature To identify the subset of hypoxia-responsive genes in melanocytes that are under HIF1a regulation, both the HIF1a-dependent and hypoxia-responsive datasets were queried for genes consistently altered under both hypoxia and siHIF1a KD conditions (Table S6 ). This analysis identified 251 genes that were comprised of two opposing cohorts: 185 genes that are both upregulated under hypoxia and downregulated in response to siHIF1a KD, and have HIF1a pathway members as the top predicted upstream regulators; and 66 genes that are both downregulated under hypoxia and upregulated in response to siHIF1a KD. Contained within this melanocyte 251 gene signature were diverse cellular processes consistent with a hypoxia-and HIF1a-mediated response (Table S7) . Upregulated genes were enriched for known HIF1a-activated hypoxia targets, many of which correspond to the enriched biological processes of glycolysis, MTORC1 signaling, epithelial-to-mesenchymal transition (EMT), heme metabolism, and angiogenesis. Processes enriched within the downregulated gene signature included the GM2 checkpoint of the cell cycle, MTORC1 signaling, unfolded protein response, xenobiotic metabolism, and TGFB signaling. In total, this melanocyte-defined response to HIF1a/hypoxia signaling captures a cell state switch from proliferative growth to a pro-migratory, slower cycling cell state, a condition that is known to be associated with hypoxia (O'Connell et al., 2013; Widmer et al., 2013) .
HIF1a genomewide binding
To identify specific genomic regions defining HIF1a binding in melanocytes under hypoxic conditions and facilitate the assessment of HIF1a direct targets, chromatin immunoprecipitation (ChIP) was performed in melanocytes that had been subjected to 24-h hypoxia conditions. Enrichment of HIF1a binding at control loci was confirmed by qPCR, which showed HIF1a binding at the proximal promoters of the known HIF1a target genes Kdm6b/Jmjd3 and Kdm3a, both of which are involved in chromatin histone modifications ( Figure 2A ). Subsequent next-generation sequencing of two HIF1a-ChIP bioreplicate samples (ChIP-Seq) identified 1773 HIF1a chromatin binding regions/peaks genomewide ( Figure 2B , Table S8 ).
Assessment for the enrichment of known HIF1a consensus binding within these 1773 HIF1a-ChIP peak summit regions found enrichment of the motif ACGTG(A/ C), which encompasses the HIF1a:ARNT binding motif (A/ G)CGTG (E-value = 1.2 e-18). The positions of the genomewide HIF1a-ChIP peaks were also assessed relative to annotated RefSeq genes. Of the 1773 HIF1a binding peaks, 987 (56%) resided either within gene annotations or in the flanking 5-kb upstream and downstream regions of RefSeq gene annotations, while 44% resided in distal intergenic regions ( Figure 2C ). Given the large number of HIF1a binding regions distal to gene annotations, regions in close proximity to TSS were selected. A total of 537 HIF1a-ChIP peaks located within AE5 kb of TSSs of individual genes were identified. These TSS peaks correlated with 591 Ensembl annotated genes ( Figure 2B , Table S9 ). Pathway analysis for these 591 HIF1a-ChIP-associated genes identified HIF1a-regulated networks, as well as pathways reflective of a metabolic shift toward glycolysis ( Figure 2D ). These HIF1a peaks and associated genes represent the first comprehensive inventory of putative HIF1a binding locations associated with transcriptional targets in melanocytes under hypoxia.
HIF1a direct target genes in melanocytes
Given that hypoxia can regulate HIF1a-dependent as well as HIF1a-independent pathways, and also that HIF1a can have indirect, downstream effects, we sought to identify genes in the melanocyte-specific datasets that were putative direct targets for HIF1a. HIF1a direct targets were defined by their presence in both the 591 HIF1a ChIP-associated gene dataset and the hypoxia-responsive and/or the HIF1a-dependent gene sets. These criteria identified 81 HIF1a direct targets: 30 genes changed only under hypoxia conditions, 15 genes altered only by siHIF1a KD, and 36 genes consistently altered under both HIF1a upregulation by hypoxia and siHIF1a KD ( Figure 3A , Table S10 ). Most of these 81 HIF1a direct targets (78%; 63/81) were activated by HIF1a/hypoxia signaling; however, 18 of 81 (22%) were consistent with repression by HIF1a in melanocytes.
Of the 81 HIF1a direct target genes, 51% (41/81) have been previously identified as known members of hypoxia-responsive pathways in other tissues (Table S10 ). These known HIF1a targets were enriched for cellular functions including chromatin remodeling (Kdm5b and Kdm6b/Jmjd6), mitochondrial proteins regulating autophagy (Bnip3, Bnip3l, and Fam162a), and a notable enrichment of proteins regulating glycolysis/ gluconeogenesis (Hk2, Gapdh, Pkm, Pgk1, Pfkl, Pdk1, Pgm2/PGM1, Pgam1, Pfkp, Ldha, and Slc16a3). The presence of these 41 known targets in the HIF1a direct target gene set validates the HIF1a-ChIP binding dataset and also defines the specific gene family members utilized in melanocytes to regulate these known HIF1a pathways. The remaining 49% (40/81) of the HIF1a direct target genes were novel HIF1a targets. Interestingly, cellular functions associated with the set of 40 novel HIF1a direct target genes were also consistent with HIF1a-regulated cellular mechanisms, including lipid and carbohydrate metabolism (Unc13a, Aloxe3 and Epm2a), mitochondrial function (Mrpl54), cell migration (Tnfsf9), cell adhesion/repulsion (Unc5a and Adgrl1), and chromatin remodeling (Suv420 h1/KMT5B) (Barderas et al., 2013; Gene Ontology Consortium, 2015; Yang et al., 2008) .
One of the novel HIF1a direct targets (PRELID2) and three previously known HIF1a targets (KDM3A, NAMPT, and SAP30) were selected for secondary validation in 501mel melanoma cells under 48-h siHIF1a KD and 24-h hypoxia conditions ( Figure 3B ). The mRNA expression of all four genes was significantly altered in response to siHIFa KD, consistent with these genes being differentially regulated by HIF1a in both melanocytes and melanoma cells. Additional validation of HIF1a protein binding at 21 of 40 of the novel genes was found in other ChIP datasets (Table S10 ; Mimura et al., 2012; Mole et al., 2009; Salama et al., 2015) . Taken together, the identification of 40 novel HIF1a direct target genes expands the repertoire of HIF1a targets, justifying further investigation of HIF1a in the regulation of these genes both during melanocyte development and melanoma progression.
Enriched motifs localized at HIF1a binding peak summits The 81 HIF1a direct target genes in melanocytes corresponded to 89 HIF1a-associated ChIP-Seq peaks. These peaks were examined for overrepresented motifs at the HIF1a-ChIP summit binding regions. For 63 of the 89 gene-associated peaks, the three most enriched motifs contained the well-known HIF1a:ARNT consensus motif RCGTG ( Figure 3C ). However, similar to what has been observed in other tissues with different HIF1a antibodies (Mole et al., 2009; Tausendsch€ on et al., 2015) , not all HIF1a target gene peaks contained an underlying RCGTG consensus motif. In addition, HIF1a showed a broad enrichment pattern across an 80-bp window centered on the peak summit, rather than one central, discrete motif ( Figure 3D ). This pattern is similar to that described for E2F proteins, and suggests HIF1a may associate with other DNA-protein complexes to regulate target gene expression (Bailey and Machanick, 2012) .
As the HIF1a direct target binding profile suggested the presence of additional DNA-protein complexes, the analysis was expanded to include the full genomespanning set of 1773 HIF1a-ChIP peaks, to identify overrepresented, centrally located motifs near peak summits. Along with the broad, centrally located motif profile of the HIF1a:ARNT consensus motif (P-value = 1.6 e-16), additional motif sequences with discrete region enrichment locations relative to the HIF1a peak summit coordinates ( Figure S1 ) were found. These profiles were as follows: (i) a single, centrally located distribution profile for multiple motifs corresponding to members of the RFX family of proteins (P-values ranging from 1.1 e-46 to 1.2 e-27) ( Figure S2 ); (ii) motifs present on either side of the HIF1a summit, associated with proteins NRF1 (Pvalue = 8.6 e-14), ZNF524 (P-value = 5.7 e-10), and GMBE2 (P-value = 1.6 e-7) in addition to the unassigned motif GGTTCGA(A/T) (P-value = 3.5 e-21); and (iii) two motifs distributed broadly across the area surrounding HIF1a peak summits corresponding to XBP1 and KLF12 proteins (P-values = 5.5 e-7 and 5.5 e-7, respectively). Both the proximity of and distinct locations for these motifs relative to the peak summit suggest the potential for coordinated gene regulation between HIF1a and these factors or family members, and possible complex or coordinated binding. Table S10 for the complete list of 81 HIF1a direct target genes. ARNT, aryl-hydrocarbon-receptor nuclear translocator.
HIF1a direct target genes correlate with disease-free status Animal models have shown that HIF1a is involved in melanoma tumor progression from the primary tumor to lymph node metastasis (Hanna et al., 2013) . Therefore, the 81 HIF1a direct target genes in melanocytes were examined for gene expression level differences in primary melanoma tumors that correlate with progression to metastatic disease. Clinical and gene expression data from the cutaneous melanoma provisional dataset of The Cancer Genome Atlas (TCGA) Research Network [http://cancergenome.nih.gov/ (Cancer Genome Atlas Network, 2015)] were queried for correlation of gene expression levels to the clinical metric Disease-free status (DFS). DFS is a measure of tumor metastasis arising following resection of the primary tumor. As a control, the clinical parameters associated with this dataset were examined to confirm that worse prognosis correlates with increased tumor staging. Tumor staging is measured by standardized American Joint Committee on Cancer (AJCC) parameters, in which stage I and stage II describe localized tumor growth, and the transition from stage II to stage III is marked by the appearance of regional metastasis (Boland and Gershenwald, 2016) . Similar to other clinical cohorts, the TCGA melanoma dataset demonstrated significant correlation of both DFS and overall survival (OS) with primary tumor progression from stage II to stage III ( Figure S3) .
First, the cohort of TCGA primary melanoma tumors was evaluated for correlation of DFS or OS with the expression profiles for the nine genes identified as differentially expressed in response to hypoxia in multiple tissues (BNIP3, ADM, BHLHE40, BNIP3L, IGFBP3, MXI1, P4HA1, SLC2A3, and VEGF). Logistic regression found no correlation between DFS and OS in primary tumors for either individual gene expression, or for expression of the panel of these nine genes together (data not shown).
Next, the 81 HIF1a direct target genes in melanocytes were examined for correlation with clinical metrics in the TCGA primary melanoma tumors. Interestingly, expression levels for 10 individual genes were significantly correlated with DFS in the primary tumors ( Figure 4A-C) . Logistic regression analysis for gene expression for the set of 10 genes together also found that the combined profile significantly correlated with DFS in primary tumors (P-value < 0.0013) and ROC analysis revealed an area under the curve (AUC) = 0.826 (P < 0.0001, Figure 4D) , consistent with the expression changes of these 10 HIF1a direct target genes discriminating for the time course of melanoma disease progression.
The set of 10 DFS-associated, HIF1a direct targets included three previously characterized HIF1a target genes (PKM, GAPDH, and ZNF292) and seven novel genes (AGTRAP, DARS, DTWD1, GPC6, PPAT, RLF, and SEH1L). As both DTWD1 and SEH1L loci had not been previously associated with HIF1a-ChIP binding in other tissues, secondary validation of HIF1a binding was performed in an additional melanocyte HIF1a-ChIP biological replicate by qPCR. This confirmed significant enrichment of HIF1a binding at the HIF1a ChIP-Seq peak summit locations associated with DTWD1 and SEH1L ( Figure 5A) .
A subset of the novel DFS-associated genes was assessed for HIF1a-dependent expression changes in 501mel melanoma cells with siRNA-mediated HIF1a KD ( Figure 5B, C) . Consistent with what was observed in melanocytes with HIF1a KD, lower expression levels were observed for DARS, RLF, and ZNF292 in 501mel cells with HIF1a KD. However, of the three genes tested that had higher expression upon siHIF1a KD in melanocytes (AGTRAP, DTWD1, and PPAT), only AGTRAP exhibited elevated levels upon siHIF1a KD in melanoma cells, consistent with HIF1a repression. Conversely, DTWD1 and PPAT were downregulated by siHIF1a KD, thus responding as if they were activated targets in 501mel cells. Therefore, all novel targets tested were HIF1a-dependent in both melanocytes and melanoma cells, with AGTRAP consistently demonstrating repression by HIF1a signaling.
Hierarchical clustering analysis was performed for the 10 DFS-associated, HIF1a direct target genes across the entire 88 primary tumor dataset (Figure 6 ), to allow comparison of the expression of these 10 genes within individual tumors. In addition, the distribution of the 88 tumors within the expression groups that were linked to shorter or longer DFS metrics for each of the 10 DFSassociated, HIF1a direct target genes (shown in Figure 4 ) was determined by tallying the number of times each tumor was present within the high or low 25% expression groups for each gene (Figure 6 , visualized by blue and red bars on right). Strikingly, tumor clustering for gene expression aligned well with the frequency scores correlated with shorter or longer DFS metrics. A group of tumors were frequently found within the DFS profiles corresponding to better prognosis ( Figure 6 , blue bars at right), and this tumor group was defined by consistent, lower expression levels in the seven HIF1a target genes that showed lower expression correlated with longer DFS/better prognosis ( Figure 6 , upper portion). Conversely, higher expression occurred for the remaining three genes (PKM, GAPDH, and AGTRAP) within this same tumor cluster group.
In contrast, tumors more frequently associated with poor prognosis/shorter DFS ( Figure 6 , red bars at right) exhibited lower expression of PKM, AGTRAP, and GAPDH, and heterogeneous upregulation of the other seven genes, with notable tumor-to-tumor variation. This gene expression heterogeneity among tumors suggests a shorter time of DFS does not require simultaneous upregulation of all seven genes. In summary, this subset of seven HIF1a direct target genes revealed a gene expression profile that is associated with better prognostic features in primary melanoma tumors when these genes exhibit low expression levels.
Discussion
While genomic mutations in driver genes that promote MAPK signaling pathways are fundamental to melanoma initiation, it is also clear that changes in the tumor microenvironment trigger dynamic changes in tumor gene expression, impacting metastasis progression and disease prognosis. As HIF1a stabilization and activation occur in response to lowered oxygen concentration, HIF1a is positioned to be both a key cellular sensor of tumor oxygen levels and a regulatory gatekeeper of metastatic cell state. The tissue-specific nature of HIF1a genomic binding and target regulation requires a tissuefocused approach. However, melanoma tumors are inherently diverse and heterogeneous cell populations, therefore addressing HIF1a and hypoxia responses in tumor tissue imposed technical challenges. Given that murine melanoma tumor animal models have found that hypoxia and HIF1a play a key role in melanoma tumor progression (Cheli et al., 2012; Hanna et al., 2013) , we used murine immortalized melanocyte cells to understand hypoxia-and HIF1a-directed gene regulation occurring in melanocytes and to identify corresponding HIF1a targets correlated with worse outcomes for melanoma disease progression. Our identification of HIF1a direct targets using this mouse model system found that HIF1a-and hypoxia-responsive pathways regulating melanoma tumor progression are conserved across species. As new biomarkers defining cell states that predict clinical benefit are needed (Merlino et al., 2016) , our analysis reinforces the utility of murine animal models in the identification of biomarkers at key stages of melanoma progression that are correlated with disease progression in humans.
Definitive classification of transcription factor direct and indirect targets requires correct assignment of regulatory ROC curve analysis for the set of DFSassociated HIF1a direct target genes demonstrating the degree to which this set of 10 genes is predictive of DFS.
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loci to individual genes. Our conservative approach classified~11% of the siHIF1a-responsive genes as direct targets based on the location of HIF1a binding in close proximity to TSSs, consistent with what has been observed in other tissues (Mimura et al., 2012; Mole et al., 2009; Salama et al., 2015) . This may be an underestimate of HIF1a direct targets, given that over 50% of the HIF1a ChIP binding regions identified reside outside of gene structures and have the potential to regulate expression through long-range enhancers. While our analysis focused on HIF1a direct target gene regulation and function, it also provided a foundation for understanding the complexity of hypoxic cell response through HIF1a-independent and HIF1a-indirect mechanisms. Prominent examples of both include RBL1 and ATF4, the predicted transcriptional regulators of hypoxiadownregulated and siHIF1a KD-upregulated gene subsets, respectively. Both RBL1 and ATF4 have significantly altered expression levels and are predicted to be upstream regulators of multiple genes with altered expression; however, HIF1a binding was not located near either gene, suggesting neither are under HIF1a direct regulation. Our study identified multiple chromatin modifiers, DNA methylases, and transcription factors that are direct targets of HIF1a, and would themselves cause highly complex cellular responses to hypoxia that are independent and/ or indirectly regulated by HIF1a. Dissecting these downstream responses will require future studies. Along with discovering both HIF1a direct and indirect targets utilized within the melanocyte lineage, this study also revealed general trends for HIF1a chromatin binding that are broadly applicable to HIF1a binding across diverse tissue datasets. The melanocyte HIF1a-ChIP data revealed cis-regulatory binding both with and without RCGTGcontaining motifs, similar to what has been found in other tissues (Mole et al., 2009; Tausendsch€ on et al., 2015) . Even within the subset of melanocyte HIF1a binding regions with RCGTG motifs, the consensus motif was distributed broadly across the HIF1a-ChIP peak rather than at a single peak summit. Overall, these data suggest HIF1a recruitment to DNA is not solely dependent upon on the RCGTG motif, and also suggest possible recruitment by factors other than the well-characterized cofactor ARNT. Consistent with this hypothesis, multiple motifs beyond RCGTG were enriched at HIF1a binding loci, and these motifs showed specific, defined locations relative to HIF1a peak summits. One motif enriched at HIF1a-ChIP peaks is for the transcription factor XBP1, which is of interest because HIF1a-XBP1 complexes have been shown to occur at defined loci in breast cancer cells, where they drive gene expression leading to poor prognosis in triple-negative breast cancer (Chen et al., 2014) . Overall, these data highlight the need for future studies to determine more broadly how HIF1a is recruited to gene regulatory loci, what the tissue-specific DNA binding components are that recruit HIF1a to regulatory loci, and more specifically whether XBP1-HIF1a interactions also regulate gene expression correlated with prognostic outcomes in melanoma.
These studies present an unbiased, genomewide approach to characterize the melanocyte lineage-specific The disease-free statusassociated, HIF1a direct target genes show significantly altered expression upon HIF1a knockdown (KD) in 501mel cells (*P < 0.05; **P < 0.01; ***P < 0.001). No detectable expression was observed for GPC6 in 501mel cells (data not shown). HIF1a and KDM3A were included as controls.
response to hypoxia and HIF1a activation, leading to the identification of 40 novel HIF1a direct target genes. This is crucial information for deciphering HIF1a's role in melanoma progression, and again highlights that gene expression changes under hypoxia are cell specific, and thus, generalizations cannot be made across cell types. Noteworthy among the novel targets is AGTRAP, a wellcharacterized inhibitor of angiotensin II type 1 receptor [AT1R (Castrop, 2015; Cui et al., 2000; Gordan et al., 2007; Koshiji et al., 2004) ]. AGTRAP (along with PKM and GAPDH) displays higher gene expression in primary melanoma tumors with a better prognosis/longer DFS time, and overall, the results in both melanocyte and melanoma cells suggest AGTRAP is a HIF1a-repressed target. AT1R activation has been shown to promote vascularization in a mouse melanoma model (Egami et al., 2003) ; therefore, HIF1a-mediated repression of AGTRAP would facilitate AT1R upregulation and is consistent with promotion of tumor vascularization. Consistent with upregulation of the AT1R signaling pathway occurring in melanocytes under hypoxic conditions, the AT1R downstream signaling targets Cp and Amox1 are both upregulated in the hypoxia-responsive/HIF1a-dependent dataset.
In combination with the activation of signals to promote vascularization, a cell's ability to acquire invasive 
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properties that promote migration away from the primary tumor is also a critical component of melanoma metastasis. Hypoxia-responsive melanocyte genes include 45 genes with GO annotation corresponding to cell motility. Within the smaller subset of 251 hypoxia-responsive and HIF1a-dependent melanocyte genes, there were 13 EMT-associated genes (Cxcl12, Edil3, Fmod, Igfbp3, Itga2, Loxl2, Plod1, Plod2, Spp, Postn, Serpine2, Spp1, and Vegfa), of which only two genes exhibit HIF1a binding at the TSS (Plod1 and Plod2). While this suggests that HIF1a activation by hypoxia is a key regulator of multiple components of invasive cell state-associated gene signatures, it also indicates this complex regulation occurs through both HIF1a direct and indirect mechanisms.
In addition to identifying a gene profile reflecting a HIF1a-directed invasive response, this study discovered 10 HIF1a direct target genes whose expression correlates with primary melanoma tumor progression to metastasis. Interestingly, this set of 10 genes spans multiple cellular functions, which may suggest this gene profile defines a genomic cell state rather than each gene in this profile having the individual capacity to drive invasiveness. These varied cell functions include the previously noted vascularization (AGTRAP) and invasion (GPC6), in addition to transcriptional regulation (RLF and ZNF292), cellular proliferation/cell division (DTWD1 and SEH1L), and metabolism (GAPDH, PKM, PPAT, and DARS). Interestingly, RLF and ZNF292 are relatively uncharacterized proteins that demonstrate notable protein identity to each other, both within their zinc finger domains and uncharacterized C-terminal regions, suggesting related protein function and warranting further study of their downstream effects in light of their direct regulation by HIF1a. Importantly, this DFS-associated gene cohort presents a novel diagnostic gene expression metric tightly linked to invasive tumor properties in vivo, placing HIF1a in the position of regulatory gatekeeper of metastatic state in response to hypoxia.
In conclusion, this analysis defines the melanocyte lineage-specific HIF1a response to hypoxia, identifies a unique HIF1a-dependent/hypoxia-responsive gene expression signature as well as 81 HIF1a direct targets utilized in melanocytes, and reveals 10 DFS-associated HIF1a target genes which comprise a novel expression cohort profile linked with disease progression. These results also reveal how HIF1a, as a sensor of cellular microenvironment, is uniquely positioned to coordinately regulate multiple cellular functions that correlate with the timing of primary to metastatic disease progression. Given the frequency with which acquired resistance is observed under current combined targeted and immune system-based therapeutic approaches in melanoma, additional targets and drug combinations are needed. The key regulatory position in which HIF1a resides makes both HIF1a and its downstream targets attractive molecules to screen for future novel therapeutic interventions.
Methods
Cell growth conditions
Analysis of hypoxia phenotype responses (migration, HIF1a protein levels, known target expression changes), transcriptome analysis experiments under hypoxia and siHif1a conditions, and HIF1a genomewide ChIP binding experiments used the immortalized mouse melanocyte cell line melan-Ink4a-Arf À/À , obtained from Dr. Dorothy Bennett (Sviderskaya et al., 2002) . Cells were grown in RPMI media containing 200 pM Cholera Toxin and 200 nM 12-OTetradecanoylphorbol 13-acetate. Normoxic conditions were maintained in an ambient oxygen-supplemented incubator with 10% CO 2 at 37°C, providing~21% oxygen. Hypoxia-treated cells were grown at 37°C in a hypoxic chamber supplied with 1% O 2 , 5% CO 2 , 94% N 2 for 24-h. 501mel cells, obtained from Dr. Yardena Samuels, were grown in RPMI with 10% serum and 2 mM glutamine.
Migration assays were performed using 24-well Biocoat 8-lM inserts (Thermo Fisher Scientific, Waltham, MA, USA). Serumcontaining media were used as a chemoattractant below inserts. A total of 2.5 9 10 5 cells were plated in inserts using serum-free media and grown for 24 h. Three images for each of two bioreplicates/ condition were counted. HIF1a KD transfections in both human melanoma and mouse melanocyte cells were performed in triplicate using two, speciesspecific, independent siHIF1a double-strand duplex RNAs and a nonsilencing control siRNA (NC-1) according to the Lipofectamine RNAimax protocol (Invitrogen/Thermo Fisher Scientific) using 25 pmol of oligo/6-well dish. HIF1a dsRNA duplex oligonucleotides (HIF1a Dsi RNA duplex oligos) were as follows: for murine Hif1a, si6 -MMC.RNAI.N0104431.12.6 (GGACGAUGAACAUCAAGUCAGCA AC) and si1 -MMC.RNAI. N0104431.12.1 (AGACAAUAGCUUCGCA GAAUGCUCA); for Human HIF1a, si9 -HSC.RNAi.N001530.12.9 (GCACUCAAUCAAGAAGUUGCAUUAA), si5 -HSC.RNAi.N001530. 12.5 (ACCAUAUAGAGAUACACAAAGUCGG) and si4 -HSC.RNAi.N 001530.12.4 (GAUGGAAGCACUAGACAAAGUUCAC) (Integrated DNA technologies, Coralville, IA, USA). Transfections were grown under normoxic conditions for an initial 24-h, and then transferred to the hypoxic chamber for24-h, thus providing 24-h hypoxia/48-h HIF1a KD conditions.
Transcriptome analysis and differential gene expression
RNA was isolated as previously described (Fufa et al., 2015) . All experimental conditions were performed in 39 bioreplicates. Transcriptome analysis was performed using GeneChip â Mouse Gene 2.0 ST Arrays (Affymetrix/Thermo Fisher Scientific). Gene lists with false discovery rate (FDR) of 0.05 and AE1.5-fold differential expression and hierarchical clustering analyses were obtained using PARTEK (Partek Incorporated, Chesterfield, MO, USA). Analyses of differentially expressed genes, pathway enrichment, and upstream regulatory genes were obtained from INGENUITY PATHWAY ANALYSIS Software (Qiagen, Germantown, MD, USA). Quantitative changes in gene expression were assessed using STEPONE (Thermo Fisher Scientific). Statistical significance was calculated by t tests or ANOVA with Bonferroni correction using GRAPHPAD PRISM (GraphPad Software, La Jolla, CA, USA). For each condition, cDNA was made using a high-capacity cDNA reverse transcriptase kit (Applied Biosystems/Thermo Fisher Scientific). Gene expression for each bioreplicate was tested in triplicate using the relative standard curve method. TAQMAN assays used were as follows: (mouse) Hif1a, Mm00468869_m1; Kdm3a,
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Chromatin immunoprecipitation and next-generation sequencing
Approximately 2 9 10 7 cells were harvested, cross-linked at room temperature with fresh 1% formaldehyde for 9 min, and quenched with the addition of glycine to a final concentration of 125 mM for at least 15 min. Cells were then lysed on ice using 1 ml low-salt ChIP buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.5% NP-40, 1.0% Triton X-100). Sonications were performed using Qsonica Q800R (Qsonica, Newtown, CT, USA) with 70% and 10 s on, 20 s off cycles for 15 min to yield fragments of 500-100 bp. For ChIP-Seq analysis, immunoprecipitations were performed as previously described (Fufa et al., 2015) using 10 lg/IP of HIF1a antibody #AF1935 (R and D Systems, Minneapolis, MN, USA) with normal goat IgG AB-108-c (negative control) IP performed in tandem. Illumina ChIPSeq libraries were prepared as follows: ChIP-isolated DNA was size selected by 2% Agarose Nusieve gel, and a 200-500-bp region was excised and purified using Qiaquick gel extraction kit. Adapter linker attachment was performed by polymerase chain reaction (PCR) using 30 ng of DNA and 29 Phusion master mix and primers, using conditions of 30 s, 98°C, followed by 10 s, 98°C, 30 s, 65°C and 30 s, 72°C with cycle number empirically determined, followed by a final 5 min, 72°C extension step. Adapter-ligated PCRs were purified using Agencourt Ampure XP PCR Purification Beads (Beckman Coulter, Indianapolis, IN, USA) per manufacturer's protocol. Statistical significance was calculated by t tests using GRAPHPAD PRISM. Two bioreplicates and input control DNA were sequenced for over 90 million unique Illumina reads. Quality control assessment was performed using FASTQC and GALAXY (Afgan et al., 2016) . Reads were mapped to sequence build NCBI37/mm9 using BurrowsWheeler Aligner (BWA), and peak calling was performed using Model-based Analysis of ChIP-Seq (MACS1.4) at GALAXY, using a cutoff of P < 1.0 e-05. The Genomic Regions Enrichment of Annotations Tools (GREAT) (McLean et al., 2010) was used to identify the 537 HIF1a-ChIP peaks located within AE5 kb of TSSs, and the 591 genes correlated with these peaks. Enrichment of known HIF1a consensus binding within the 1773 HIF1a-ChIP peak summit regions was assessed using DREME (Machanick and Bailey, 2011) .
Assignment of peaks to genes and gene region-related structures were made using summit peak coordinates. Overrepresented motifs present within HIF1a peak summits using 400-bp windows were identified using the MEME-ChIP Suite of tools (Machanick and Bailey, 2011) .
ChIP validation qPCR
HIF1a binding enrichment to genomic regions was verified by qPCR using SYBR â Select Master Mix and three technical replicates for each bioreplicate analyzed. Relative fold-change was determined by normalizing to percent input using the ddCt method. ChIP enrichment of genomic loci was assayed using the following primers: Negative control Chr6 (CCGAGGACCGCACCATTA, AAATAACGTCCACTAA CATGAATAGCA), Jmjd3 (ACACACGAGCAAGGAACGA, AAAACTCG CTCGGTCGTG), Kdm3a (TTCAGGCGTACGCAGTTAGA, TCAAAATG GCGGACCTAGAC), Dtwd1 (AGGAAGCTGACGGTTCCTTT, GCATGC TCAGAGGGAGAATC), Agtrap (CGAACTCGGGAACAAACTTC, GACG CCGTCTCCTAGCAA), and Seh1l (GTTTTCGGAGGCGCACAC, AGCA GACGAAGCTGGGAGA).
Correlation with DFS and OS
Gene expression and clinical data for cutaneous melanoma primary tumors, a dataset generated by TCGA, were obtained from www.cb ioportal.org. Tumors (88 for DFS and 103 for OS analysis) were first ranked using the expression of each hypoxia/HIF1a target gene being queried. The top 25% of tumors (highest gene expressing tumors) and the bottom 25% of tumors (lowest gene expressing tumors) were plotted as a survival curve for DFS or OS. Significance between expression-defined, gene-specific cohorts was then assessed with respect to clinical outcome. Logistic regression analysis utilized expression data for the primary tumor expression data set and corresponding DFS and OS clinical data. FDR was calculated using Benjamini and Hochberg procedure.
Western blots
Whole cell lysates were harvested in Novex â Tris-Glycine SDS Sample Buffer (ThermoFisher Scientific) then sonicated and incubated at 95°C for 5 min. Samples were separated on a 10% Tris-Glycine gel then transferred onto PVDF membrane via iBlot (ThermoFisher Scientific). Membranes were blocked for 1 h in 5% non-fat milk, TBST followed by overnight incubation at 4°C in primary HIF1a antibody (AF1935, R&D Systems) or monoclonal a-tubulin antibody (SC-53646, Santa Cruz Biotechnology, Dallas, TX, USA). Membranes were then washed in TBST and incubated with the appropriate secondary HRP-conjugated antibody (anti-goat for HIF1a, anti-mouse for a-Tubulin; Jackson ImmunoResearch Laboratories, Bar Harbor, ME, USA). Protein band visualization was performed using Amersham ECL Prime Western Blotting Detection Reagent (RPN2232, GE Healthcare, Pittsburgh, PA, USA).
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